CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The SchistoShield project is developing a vaccine for schistosomiasis, a disease affecting millions. The vaccine aims to provide long-lasting protection against various schistosome species and is undergoing clinical trials in endemic regions to assess its safety and effectiveness.
Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries.
Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed.
Chemotherapy is the preferred method for schistosomiasis control; but the effectiveness of mass-treatment programs is compromised by reinfection requiring regular re-treatment.
An efficacious vaccine, with long-lasting protection against all schistosomiasis forms, would impact disease control.
We req…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
UGOT - GOETEBORGS UNIVERSITET/UNIVERSITY OF GOTHENBURG
Sweden, Goeteborg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Tuebingen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Burkina Faso, Ouagadougou
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
